COMMON STOCK PURCHASE WARRANT SAB BIOTHERAPEUTICS, INC.Common Stock Purchase • December 12th, 2022 • SAB Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 7, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 7, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), up to [__] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT SAB BIOTHERAPEUTICS, INC.SAB Biotherapeutics, Inc. • December 12th, 2022 • Biological products, (no disgnostic substances)
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Brookline Capital Markets, a division of Arcadia Securities, LLC, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 7, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 7, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), up to [__] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 12th, 2022 • SAB Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 6, 2022 (the “Effective Date”) by and among SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively, the “Investors”).
